KR940703676A - 알렌드로네이트를 사용한 치근막 질환의 치료방법(Treatment of periodontal disease with alendronate) - Google Patents

알렌드로네이트를 사용한 치근막 질환의 치료방법(Treatment of periodontal disease with alendronate)

Info

Publication number
KR940703676A
KR940703676A KR1019940702159A KR19940702159A KR940703676A KR 940703676 A KR940703676 A KR 940703676A KR 1019940702159 A KR1019940702159 A KR 1019940702159A KR 19940702159 A KR19940702159 A KR 19940702159A KR 940703676 A KR940703676 A KR 940703676A
Authority
KR
South Korea
Prior art keywords
administered
alendronate
amino
pharmaceutically acceptable
abp
Prior art date
Application number
KR1019940702159A
Other languages
English (en)
Other versions
KR100258667B1 (ko
Inventor
제이. 게르츠 베리
에이.로단 기데온
Original Assignee
조셉 에프.디프리마
머크 앤드 캄파니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조셉 에프.디프리마, 머크 앤드 캄파니, 인코포레이티드 filed Critical 조셉 에프.디프리마
Publication of KR940703676A publication Critical patent/KR940703676A/ko
Application granted granted Critical
Publication of KR100258667B1 publication Critical patent/KR100258667B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 하기 구조식(Ⅰ)의 유효량의 4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산 또는 일나트륨 염 3수화물(알렌드로네이트)을 포함하는 약제학적으로 허용되는 염을, 투여함을 특징으로 하여, 사람을 포함한 포유동물에서 치근막 질환을 치료하는 방법을 청구하고 있다. 본 화합물은 치근막염 및 치근막질환된 관련된 치조골 손실의 치료에 유용하다.

Description

알렌드로네이트를 사용한 치근막 질환의 치료방법(Treatment of periodontal disease with alendronate)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도∼제3도는 위약 동물에서의 밀도 손실에 대한 결착효과를 나타낸 것이다.

Claims (16)

  1. 유효량의 하기 구조식의 4-아미노-1하이드록시부틸리덴-1, 1-비스포스폰산(ABP) 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 사람을 포함한 포유동물에서 치근막 질환을 치료하는 방법.
  2. 제 1 항에 있어서, 하기 구조식의 알렌드로네이트를 투여함을 특징으로 하는 치근막 질환의 치료방법.
  3. 제 1 항에 있어서, 4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산(ABP)을 소염제와 배합하여 투여함을 특징으로 하는 치근막 질환의 치료방법.
  4. 제 3 항에 있어서, 알렌드로네이트를 소염제와 배합하여 투여함을 특징으로 하는 치근막 질환의 치료방법.
  5. 제 1 항에 있어서, 4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산(ABP) 또는 이의 약제학적으로 허용되는 염을 항미생물제와 배합하여 투여함을 특징으로 하는 치근막 질환의 치료방법.
  6. 제 5 항에 있어서, 알렌드로네이트를 항미생물제와 배합하여 투여함을 특징으로 하는 치근막 질환의 치료방법.
  7. 제 2 항에 있어서, 알렌드로네이트를 소염제 및 항미생물제와 배합하여 투여함을 특징으로 하는 치근막 질환의 치료방법.
  8. 제 1 항에 있어서, 1일 0.25 내지 80㎎의 범위 또는 1일 0.01 내지 0.8㎎/㎏의 범위의 경구용량으로 ABP 또는 알렌드로네이트를 투여함을 특징으로 하는 치근막 질환의 치료방법.
  9. 제 1 항에 있어서, 0.005 내지 0.40㎎/㎏의 정맥내 용량으로 2주 간격으로 투여함을 특징으로 하는 치근막 질환의 치료방법.
  10. 제 1 항에 있어서, 4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산(ABP) 또는 이의 약제학적으로 허용되는 염을 약제학적으로 허용되는 담체와 함께 투여함을 특징으로 하는 치근막 질환의 치료방법.
  11. 유효량의 4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산(ABP) 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 사람을 포함한 포유동물에서 치조골 손실을 치료하는 방법.
  12. 제11항에 있어서, 유효량의 알렌드로네이트를 투여함을 특징으로 하는 치조골 손실의 치료방법.
  13. 제12항에 있어서, 1일 0.25 내지 80㎎의 범위 또는 1일 0.01㎎/㎏ 내지 0.8㎎/㎏의 범위의 경구용량으로 알렌드로네이트를 투여함을 특징으로 하는 치조골 손실의 치료방법.
  14. 제12항에 있어서, 0.005 내지 0.40㎎/㎏의 정맥내 용량으로 2주 간격으로 투여함을 특징으로 하는 치조골 손실의 치료방법.
  15. 4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산 일나트륨염 3수화물(알렌드로네이트)를 약제학적으로 허용되는 담체와 함께 투여함을 특징으로 하여, 치조골 손신을 치료하는 방법.
  16. 치근막 수술에 대한 보조 치료법으로서 유효량의 4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산(ABP) 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 사람을 포함한 포유동물에서 치근막 질환을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702159A 1991-12-17 1992-12-08 알렌드로네이트를 사용한 치근막 질환 및 치근막 질환과 관련된 치조골 손실 치료용 약제학적 조성물 KR100258667B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/808,701 US5270365A (en) 1991-12-17 1991-12-17 Prevention and treatment of periodontal disease with alendronate
US7/808.701 1991-12-17
US?07/808,701? 1991-12-17
PCT/US1992/010534 WO1993011774A1 (en) 1991-12-17 1992-12-08 Treatment of periodontal disease with alendronate

Publications (2)

Publication Number Publication Date
KR940703676A true KR940703676A (ko) 1994-12-12
KR100258667B1 KR100258667B1 (ko) 2000-07-01

Family

ID=25199466

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702159A KR100258667B1 (ko) 1991-12-17 1992-12-08 알렌드로네이트를 사용한 치근막 질환 및 치근막 질환과 관련된 치조골 손실 치료용 약제학적 조성물

Country Status (22)

Country Link
US (1) US5270365A (ko)
EP (1) EP0617624B1 (ko)
JP (1) JP2825654B2 (ko)
KR (1) KR100258667B1 (ko)
AT (1) ATE150646T1 (ko)
AU (1) AU675417B2 (ko)
CA (1) CA2122498A1 (ko)
CY (1) CY2054B1 (ko)
CZ (1) CZ282902B6 (ko)
DE (1) DE69218624T2 (ko)
DK (1) DK0617624T3 (ko)
ES (1) ES2100519T3 (ko)
GR (1) GR3022951T3 (ko)
HK (1) HK1000114A1 (ko)
HU (1) HU221807B1 (ko)
IL (1) IL104109A (ko)
LV (1) LV12084B (ko)
NO (1) NO306197B1 (ko)
NZ (1) NZ246274A (ko)
SK (1) SK280628B6 (ko)
WO (1) WO1993011774A1 (ko)
ZA (1) ZA929712B (ko)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW237386B (ko) * 1992-04-15 1995-01-01 Ciba Geigy
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
JPH09511927A (ja) * 1994-04-18 1997-12-02 ザ、プロクター、エンド、ギャンブル、カンパニー 歯槽骨へのビスホスホネート類のイオン導入デリバリー
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
KR19980702210A (ko) * 1995-02-17 1998-07-15 폴락 돈나 엘 비척추골 골절의 위험률을 감소시키는 방법
WO1996035407A1 (en) * 1995-05-12 1996-11-14 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
EP0886521B1 (en) * 1996-02-14 2003-05-21 Itzhak Binderman Topical bisphosphonates for prevention of bone resorption
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
JP2000511178A (ja) * 1996-05-17 2000-08-29 メルク エンド カンパニー インコーポレーテッド 発泡性ビスホスホネート製剤
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
BR9712197A (pt) * 1996-10-04 1999-08-31 Merck & Co Inc Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso.
US5773429A (en) * 1996-12-11 1998-06-30 Fuisz Technologies Ltd. Drug combination for treating calcium loss
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
ID24096A (id) * 1997-07-22 2000-07-06 Merck & Co Inc Metode untuk menghambat resorpsi tulang
FR2784031B1 (fr) * 1998-10-02 2002-02-01 Sanofi Elf Utilisation de derives de l'acide bisphosphonique pour la preparation d'un medicament destine au traitement des boiteries
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
PL349438A1 (en) * 1998-12-23 2002-07-29 Jomaa Pharmaka Gmbh Use of bisphosphonates for the prevention and treatment of infectious processes
US6315566B1 (en) 1999-05-18 2001-11-13 3M Innovative Properties Company Dental materials
US6143919A (en) * 1999-05-18 2000-11-07 3M Innovative Properties Company Polymerizable acidic compounds and methods of preparation
PL196485B1 (pl) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20040053968A1 (en) * 2001-12-28 2004-03-18 Hartman George D. Methods and compositions for treating peridontal disease
US20070094865A1 (en) * 2002-01-10 2007-05-03 Ji-Guang Zhang Packaged thin film batteries and methods of packaging thin film batteries
US7960054B2 (en) * 2002-01-10 2011-06-14 Excellatron Solid State Llc Packaged thin film batteries
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
FR2838339B1 (fr) * 2002-04-12 2005-06-24 Univ Angers Derives poly-phosphonates pour compositions dentifrices
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
US20050142185A1 (en) * 2003-12-29 2005-06-30 Beleno Alfredo B. Softgel formulations of bisphosphonates bone resorption inhibitors
US20060034921A1 (en) * 2004-01-05 2006-02-16 Katdare Ashok V Effervescent bisphosphonate formulation
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US7731765B2 (en) 2004-02-20 2010-06-08 Excellatron Solid State, Llc Air battery and manufacturing method
US20080070087A1 (en) * 2004-02-20 2008-03-20 Excellatron Solid State, Llc Non-volatile cathodes for lithium oxygen batteries and method of producing same
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
KR100564628B1 (ko) * 2004-06-16 2006-03-28 삼성전자주식회사 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
WO2007044904A2 (en) * 2005-10-11 2007-04-19 Ji-Guang Zhang Method of manufacturing lithium battery
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
JP2013501056A (ja) 2009-08-03 2013-01-10 キメリクス，インコーポレイテッド ウイルス感染およびウイルス誘発腫瘍を治療する組成物および方法
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
RU2449761C1 (ru) * 2011-03-09 2012-05-10 Светлана Минифаритовна Алетдинова Способ лечения хронических апикальных периодонтитов
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
RU2713257C1 (ru) * 2019-05-06 2020-02-04 Жанна Владимировна Вечеркина Способ лечения хронического апикального периодонтита

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3429963A (en) * 1964-06-09 1969-02-25 Colgate Palmolive Co Dental preparation containing polymeric polyelectrolyte
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4042679A (en) * 1975-11-07 1977-08-16 Colgate-Palmolive Company Antibacterial oral composition
US4138477A (en) * 1976-05-28 1979-02-06 Colgate Palmolive Company Composition to control mouth odor
US4440779A (en) * 1981-06-30 1984-04-03 Merck & Co., Inc. Tricyclic derivatives of substituted pyrrole acids as analgesic and anti-inflammatory agents
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4677132A (en) * 1986-03-12 1987-06-30 American Home Products Corporation Inhibition of bone resorption by etodolac
IL84494A (en) * 1986-11-21 1992-08-18 Ciba Geigy Ag Heteroaryl substituted aminomethane-diphosphonic acids,their preparation and pharmaceutical compositions containing them
EP0272208B1 (de) * 1986-11-21 1991-06-12 Ciba-Geigy Ag Aromatisch substituierte Azacyclo-alkylalkandiphosphonsäuren
HU199151B (en) * 1987-03-10 1990-01-29 Yamanouchi Pharma Co Ltd Process for producing bis-phosphonic acid derivatives
US4816437A (en) * 1987-06-01 1989-03-28 Trustees Of Boston University Methods for inducing general and localized bone apposition in-vivo
EP0317505A1 (de) * 1987-11-13 1989-05-24 Ciba-Geigy Ag Neue Azacycloalkylalkandiphosphonsäuren
GB8726714D0 (en) * 1987-11-14 1987-12-16 Beecham Group Plc Compounds
EP0320455B1 (de) * 1987-12-11 1993-06-09 Ciba-Geigy Ag Araliphatylaminoalkandiphosphonsäuren
US4877603A (en) * 1987-12-18 1989-10-31 The Procter & Gamble Company Oral compositions
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4990503A (en) * 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
GB9008433D0 (en) * 1990-04-12 1990-06-13 Beecham Group Plc Novel compositions
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof

Also Published As

Publication number Publication date
SK72794A3 (en) 1995-04-12
CZ282902B6 (cs) 1997-11-12
CZ148794A3 (en) 1995-03-15
ATE150646T1 (de) 1997-04-15
NO306197B1 (no) 1999-10-04
NO942267D0 (no) 1994-06-16
DK0617624T3 (da) 1997-04-21
IL104109A0 (en) 1993-05-13
EP0617624A1 (en) 1994-10-05
CA2122498A1 (en) 1993-06-24
ES2100519T3 (es) 1997-06-16
DE69218624D1 (de) 1997-04-30
ZA929712B (en) 1993-06-14
JPH07502506A (ja) 1995-03-16
AU675417B2 (en) 1997-02-06
SK280628B6 (sk) 2000-05-16
HU221807B1 (hu) 2003-01-28
NO942267L (no) 1994-06-16
EP0617624B1 (en) 1997-03-26
WO1993011774A1 (en) 1993-06-24
GR3022951T3 (en) 1997-06-30
KR100258667B1 (ko) 2000-07-01
HUT68788A (en) 1995-07-28
NZ246274A (en) 1997-02-24
LV12084B (en) 1998-11-20
JP2825654B2 (ja) 1998-11-18
AU3242093A (en) 1993-07-19
CY2054B1 (en) 1998-04-30
HU9401378D0 (en) 1994-08-29
IL104109A (en) 1997-02-18
DE69218624T2 (de) 1997-08-07
HK1000114A1 (en) 1997-12-05
US5270365A (en) 1993-12-14
LV12084A (lv) 1998-07-20

Similar Documents

Publication Publication Date Title
KR940703676A (ko) 알렌드로네이트를 사용한 치근막 질환의 치료방법(Treatment of periodontal disease with alendronate)
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
ES2169046T3 (es) Analogo de prostaglandina para el tratamiento de la osteoporosis.
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
RU94045155A (ru) Способы ингибирования болезни альцгеймера
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
ATE14076T1 (de) Galenische zubereitung.
ATE157252T1 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
RU98101105A (ru) Новое применение в медицинских целях
FI923662A0 (fi) Terapeutiska medel.
DK0612246T3 (da) Farmaceutiske sammensætninger af galliumkomplekser med 3-hydroxy-4-pyroner
KR950702413A (ko) 암치료에 2-(4-(4-클로로페닐)시클로헥실)-3-히드록시-1, 4-나프토퀴논을 사용하는 방법(use of 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone for the treatment of cancer)
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
KR910018026A (ko) α-페닐-α피리딜알칸산 유도체를 함유하는 배뇨장애증상 치료제
ECSP003616A (es) Micofenolato mofetil en asociacion con peg-ifn-alfa

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050114

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee